Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lazertinib +/- Bevacizumab in EGFR+ NSCLC with Smoking History
NCT06156527Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Sep 2023
- Primary completion
- Sep 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lazertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Progression-Free Survival. Started Sep 2023; status: recruiting.
02
Drugs
lazertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06156527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06156527.